Psych Capital Plc Logo

Psych Capital Plc

A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.

PSY | IL

Overview

Corporate Details

ISIN(s):
GB00BL6CJQ54
LEI:
213800WXCQ1C6GPLHH68
Country:
United Kingdom
Address:
17 HANOVER SQUARE, W1S 1BN LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shortwave Life Sciences Plc, formerly Psych Capital Plc, is a life sciences company focused on developing innovative treatments for mental health conditions. The company has transitioned from its prior role as an investment and media firm to a dedicated drug development entity following its acquisition of Short Wave Pharma. Its primary clinical program focuses on advancing psilocybin as a potential breakthrough therapy for anorexia nervosa, a condition with no FDA-approved medication. Rooted in the Israeli innovation ecosystem, Shortwave employs an IP-driven, capital-efficient strategy, utilizing strategic partnerships to optimize its drug discovery and development processes for eating disorders and other mental health indications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 08:00
Board/Management Information
Direction, Director Changes and Medical Adviser
English 20.9 KB
2025-08-19 13:50
Major Shareholding Notification
Holding(s) in Company
English 56.0 KB
2025-08-04 12:00
Board/Management Information
Clarification on Strategic Advisor Appointment
English 6.0 KB
2025-07-29 08:00
Share Issue/Capital Change
£250k Fundraising, New Directors & Review
English 27.3 KB
2025-06-24 14:10
Major Shareholding Notification
AQSE Only - Holding(s) in Company
English 56.2 KB
2025-06-16 11:21
Major Shareholding Notification
Holding(s) in Company
English 56.2 KB
2025-01-31 17:52
Earnings Release
Interim Results to 31 October 2024
English 115.6 KB
2024-12-23 13:00
Share Issue/Capital Change
Pre-Crowdfunding re Groundbreaking Treatment
English 9.5 KB
2024-11-29 16:16
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-11-27 15:12
Board/Management Information
Director Appointment and SPA Update
English 26.7 KB
2024-10-31 18:39
Annual Report
YEAR ENDED 30 APRIL 2024 AND DIRECTOR RESIGNATION
English 176.8 KB
2024-09-19 08:00
Regulatory News Service
Positive Pre-Clinical Result Drive to Human Trials
English 10.7 KB
2024-07-31 13:05
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-07-17 18:20
Major Shareholding Notification
TR1: Notification of Major Holdings
English 75.8 KB
2024-07-08 08:00
Share Issue/Capital Change
Company’s Patent Claims Confirmed
English 31.5 KB

Automate Your Workflow. Get a real-time feed of all Psych Capital Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Psych Capital Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.